GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can a Filed Plan Cover Every Disease?

No. A filed regenerative-medicine plan in Japan is not blanket permission to treat every disease, and filing is not government approval of a treatment’s effectiveness. Check whether your diagnosis, eligibility and proposed procedure match the current plan. Do not assume that each diagnosis needs a different plan number, or that one number automatically covers all the treatments a clinic advertises. Japan’s Safety Act requires a plan describing the proposed care and provides procedures for changing it 4980.

Here, “covers” means the scope described in a provision plan, not insurance reimbursement. This is general regulatory information, not personal medical advice.

Can a Filed Plan Cover Every Disease?

What a plan number tells you

A plan number identifies a filing. It does not, by itself, tell you whether the treatment offered to you matches that filing or has convincing evidence of benefit. As of 30 June 2026, MHLW reported 6,743 treatment plans and 85 research plans. The treatment total comprised 8 Class I, 2,463 Class II and 4,272 Class III plans. These are counts of plans, not patients helped or treatments proven effective 001590173.pdf.

For care subject to the Safety Act, the hospital or clinic must obtain the required certified-committee opinion and submit its provision plan before providing the described care. The requirements depend on the risk class; a higher class does not mean greater effectiveness Plan.

Ask: “Where in the current plan is my diagnosis and the procedure you are offering me described?” A number on a brochure is not enough.

Check the treatment, not just the disease name

The Safety Act requires information about the institution, proposed treatment, cell procurement, manufacturing and quality control, safety measures and reviewing committee. Check the current plan together with its supporting documents, rather than relying on the clinic’s treatment name alone 4980.

What to compare before accepting an offer
Document detail Question to resolve
Institution and responsible clinician Do these match the place and clinician offering the treatment?
Target condition and eligibility Is your diagnosis included, and do you meet the stated criteria?
Cell source, type and processing Does the offer use the preparation described in the documents?
Route, dose and treatment schedule Do the injection or infusion and planned sessions match?
Plan version, committee opinion and consent Do the documents refer to the same current treatment?

A different diagnosis does not automatically establish that a separate plan number is required. Equally, a shared number does not establish that both diagnoses are included. If the offered care falls outside the current documents, ask which valid plan or amendment addresses it. Article 5 provides for plan changes, including advance submission of non-minor changes; do not assume that every change creates a new number 4980.

Filing, approval and research are different

Start from the MHLW regenerative-medicine portal to find official plan information and the relevant public records Index. Identify which regulatory route the clinic is describing before interpreting its documents.

Three records and their limits
Record What it helps establish What it does not establish
Filed provision plan What care the provider has described under the Safety Act Product marketing approval or proof of benefit for you Plan
Product approval The named product and its approved indications and conditions of use Approval of every use of similar cells or of a clinic’s entire menu 000280868.pdf
Trial registration A study’s registered protocol and status Successful results simply because the study is registered En top

Product approvals follow the Pharmaceuticals and Medical Devices Act. PMDA’s presentation dated 20 May 2026 reported 26 currently approved regenerative medical products. That product total and the filing total above use different legal routes, units and dates; dividing them does not produce an approval rate 000280868.pdf.

Why evidence must match the proposed use

Similar cells do not mean the same treatment

A study of one preparation cannot establish that another preparation works for a different condition. Ask for human evidence matching the diagnosis, disease stage, cell source, processing, dose and route. An intravenous infusion and an injection into a joint are not interchangeable descriptions of treatment. Committee review and filing should not be dismissed as meaningless paperwork, but neither should they be presented as proof that the intervention works.

An approved product has defined indications

In the United States, Ryoncil is an allogeneic, bone-marrow-derived mesenchymal stromal cell therapy approved for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. This is a complication after donor transplantation that has not responded adequately to steroids. It is not an approval for unrelated diseases or other clinics’ cell preparations Lookup.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659.

The label describes a prospective, multicenter, single-arm study: 55 patients enrolled and 54 received treatment, with treated ages ranging from 7 months to 17 years. At day 28, 16 of the 54 treated children had a complete response and 22 had a partial response, reported as 30% and 41%. The median duration of response was 54 days, measured from the day-28 response to progression, new systemic treatment or death. These results are not a long-term cure rate or a randomized comparison with another treatment Lookup.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659.

The initial labeled regimen is 2 × 106 MSC/kg by intravenous infusion twice weekly for four weeks; further treatment depends on response. Common adverse reactions include infections, fever, bleeding, swelling, abdominal pain and high blood pressure. The label also warns about hypersensitivity and acute infusion reactions. This U.S. example illustrates how specific a product’s evidence and labeling are; it does not establish Japanese approval, suitability for you or benefit from another MSC treatment Lookup.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659.

A document-check scenario

Suppose you have knee osteoarthritis and diabetes, and a clinic offers one cell treatment for both. This is a hypothetical document check, not a patient case. Make a separate row for each diagnosis. Next to each, record the plan number, the page naming the condition, the proposed procedure and the supporting human evidence. A match for one diagnosis does not answer the question for the other.

If the documents mention only knee osteoarthritis, ask: “Please show where diabetes is included in the current plan or identify the applicable plan or amendment.” Do not infer coverage from a broad phrase such as “regenerative treatment.” Even a document match does not establish benefit or personal eligibility; an appropriately qualified physician still needs to assess your condition and alternatives.

What to request before paying

  1. Get the exact plan number and current documents. Ask for the institution’s Japanese name and address, the responsible clinician, the plan version and date, and the committee opinion.
  2. Check each diagnosis and eligibility rule. Compare your medical records with the listed indications and exclusions. If the Japanese wording is unclear, obtain a reliable translation rather than guessing.
  3. Match the proposed procedure. Use the first table to compare the quote, plan, consent form and treatment schedule. Ask the provider to explain any mismatch in writing.
  4. Confirm the official record. Use the MHLW portal. If you cannot locate the relevant document, request a current official record and a way to confirm its status with the responsible authority Index.
  5. Ask for evidence and risk information. Request the human study, sample size, comparison group, outcomes, follow-up and adverse events for the offered preparation. Check who will manage complications after you return home.
  6. Resolve gaps before committing. When assessing a treatment provider, treat unresolved document mismatches as unverified claims. Ask what the quoted price includes and discuss established treatment options with your own physician before paying.

Have an offer in hand? Bring the plan number and the page that lists your diagnosis, and ask for written confirmation before you pay.

Ask for a document check

The bottom line

Check every diagnosis against the current documents; never treat a filed plan as permission to treat every disease. The scope of the plan, the evidence for benefit and your suitability for treatment are three separate questions. Ask for a written answer to each.

Sources

  1. Japanese Law Translation — Act on the Safety of Regenerative Medicine, especially Articles 4 and 5
  2. MHLW — implementation figures as of 30 June 2026 (PDF)
  3. MHLW — provision-plan procedures under the Safety Act
  4. MHLW — regenerative-medicine portal
  5. PMDA — regenerative medical products presentation, 20 May 2026 (PDF)
  6. MHLW — Japan Registry of Clinical Trials
  7. DailyMed, U.S. National Library of Medicine — Ryoncil prescribing information, sections 1, 2, 5, 6 and 14